Broussonetia kazinoki Siebold stimulates immune response in ovalbumin-immunized mice |
Jung, Da-Young
(Herbal Medicine EBM Research center, Korea Institute of Oriental Medicine)
Ha, Hye-Kyung (Herbal Medicine EBM Research center, Korea Institute of Oriental Medicine) Lee, Ho-Young (Herbal Medicine EBM Research center, Korea Institute of Oriental Medicine) Lee, Jin-Ah (Herbal Medicine EBM Research center, Korea Institute of Oriental Medicine) Jeong, Seung-Il (Jeonju Biomaterials Institute) Choi, Young-Jae (ChunYang Paper Co., Ltd.) Shin, Hyeun-Kyoo (Herbal Medicine EBM Research center, Korea Institute of Oriental Medicine) |
1 | Lee HJ, Park JH, Jang DI, Ryu JH. Antioxidant components from Broussonetia kazinoki. Yakhak Hoechi. 1997;41(4):439-443. |
2 | Roswitha F, Thomas M, Brigitte K, Paul GS. Stimulation nitric oxide synthesis by the aqueous Extract of Panax ginseg root in RAW 264.7 cells. Br J Pharmacol. 2001;134(8):1663-1670. DOI ScienceOn |
3 | Abbas AK, Lichtman AH. Basic immunology, functions and disorders of the immune system. 2nd ed. Philadelphia:Saunders. 2004. |
4 | Tizard IR. Veterinary immunology an introduction, 6th ed. Philadelphia:Saunders. 2000. |
5 | Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses the alternative approaches. Annu Rev Immunol. 1997;15: 297-322. DOI ScienceOn |
6 | Schirmbeck R, Melber K, Kuhrber A, Janowicz ZA. Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted cytotoxic T lymphocyte responses in vivo. J Immunol. 1994;152(3):1110-1119. |
7 | Bae KH. Medical plants of Korea. Seoul:Kyohak publishing Co. 2000:65. |
8 | Ryu JH, Ahn H, Lee HJ. Inhibition of nitric oxide production on LPS-activated macrophages by kazinol B from Broussonetia kazinoki. Fitoterapia. 2003;74(4):350-354. DOI ScienceOn |
9 | Ko HH, Yen MH, Wu RR, Won SJ, Lin CN. Cytotoxic isoprenylated flavans of Broussonetia kazinoki. J Nat Prod. 1999;62(1):164-166. DOI ScienceOn |
10 | Zhang PC, Wang S, Wu Y, Chen RY, Yu DQ. Five new diprenylated flavonols from the leaves of Broussonetia kazinoki. J Nat Prod. 2001;64(9): 1206-1209. DOI ScienceOn |
11 | Tsukamoto D, Shibano M, Kusano G. Studies on the constituents of Broussonetia Species X. Six new alkaloids from Broussonetia kazinoki Sieb. Chem Pharm Bull. 2001a;49(11):1487-1491. DOI ScienceOn |
12 | Shibano M, Kitagawa S, Nakamura S, Akazawa N, Kusano G. Studies on the constituents of Broussonetia species. II Six new pyrrolidine alkaloids, broussonetine A, B, E, F and broussonetinine A and B, as inhibitors of glycosidases from Broussonetia kazinoki Sieb. Chem Pharm Bull. 1997;45(4):700-705. DOI ScienceOn |
13 | Shibano M, Nakamura S, Akazawa N, Kusano. Studies on the constituents of Broussonetia species. III. Two new pyrrolidine alkaloids, broussonetinines G and H, as inhibitors of glycosidase from Broussonetia kazinoki Sieb. Chem Pharm Bull. 1998;46(6):1048-1050. DOI ScienceOn |
14 | Shibano M, Tsukamoto D, Fujimoto R, Masui Y, Sugimoto H, Kusano G. Studies on the constituents of Broussonetia species. VII. Four new pyrrolidine alkaloids, broussonetines M, O, P, and Q, as inhibitors of glycosidase from Broussonetia kazinoki Sieb. Chem Pharm Bull. 2000;48(9):1281-1285. DOI ScienceOn |
15 | Tsukamoto D, Shibano M, Okamoto R, Kusano G. Studies on the constituents of Broussonetia species VIII. Four new pyrrolidine alkaloids, broussonetines R, S, T, and V and a new pyrroline alkaloid, roussonetine U, from Broussonetia kazinoki Sieb. Chem Pharm Bull. 2001b;49(4):492-496. DOI ScienceOn |
16 | Baek YS, Ryu YB, Curtis MJ, Ha TJ, Rengasamy R, Yang MS, et al. Tyrosinase inhibitory effects of 1,3-diphenylpropanes from Broussonetia kazinoki. Bioorg Med Chem. 2009;17(1):35-41. DOI ScienceOn |
17 | HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine. 2002;20(S3):S34-S39. DOI |
18 | Livingston PO, Adluri S, Helling F, Yao TJ, Kensil CR, Newman MJ, et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine. 1994;12(14):1275-1280. DOI ScienceOn |
19 | Cox JC, Coulter AR. Adjuvants-a classification and review of their modes of action. Vaccine. 1997;15(3):48-56. |
20 | Pascual DM, Morales RD, Gil ED, Munoz LM, Lopez JE, Casanueva, OLJ. Aduvants present regulatory challenges. Vaccine. 2006;24(S2): S88-S89. DOI |
21 | Relyveld EH, Bizzini B, Gupta RK. Rational approaches to reduce reactions man to vaccines containing tetanus and diphtheria toxoids. Vaccine. 1998;16(9-10):1016-1023. DOI ScienceOn |